Table 1.
Characteristics of patients in the phase II randomized trial*
| Characteristic | Genistein treatment group | Untreated control group |
| Patients, No. | 12 | 12 |
| Mean age (range), y | 57 (44–67) | 58 (48–73) |
| Race, No. (%) | ||
| White | 9 (75) | 9 (75) |
| African American | 2 (17) | 2 (17) |
| Other | 1 (8) | 1 (8) |
| Clinical stage, No. (%) | ||
| T1 | 7 (58) | 6 (50) |
| T2 | 4 (33) | 4 (33) |
| Unknown | 1 (8) | 2 (17) |
| Mean PSA level (SD), ng/mL | 6 (2.0) | 6 (1.9) |
| Gleason score, No. (%) | ||
| 6 | 7 (58) | 7 (58) |
| 7 | 5 (42) | 5 (42) |
| Mean presurgery treatment time (SD), wk | 4 (2.1) | N/A |
*
Two-sided t tests were used to obtain P values. A P value of more than .05 was considered not statistically significant for differences between treatment and control groups. All P values were not statistically significant. No serious adverse events, defined as grade of 2 or greater for clinical toxicity according to the National Cancer Institute's Common Toxicity Criteria, version 2.0, were observed. PSA = prostate-specific antigen; N/A = not applicable.